Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
- Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales -
- Rasayana to assume all responsibility and costs for SYN-020 development and commercialization -
ROCKVILLE, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported the out-licensing of SYN-020, to Rasayana Therapeutics, Inc., a privately-held company targeting the Gut-Organ axis biology to discover and deliver transformative gut-targeted medicines for patients with chronic inflammatory diseases.
SYN-020 is a recombinant bovine intestinal alkaline phosphatase (IAP) produced under cGMP conditions and formulated for oral delivery to the small intestine. It is designed to reduce fat absorption and intestinal inflammation; tighten the gut barrier to mitigate leaky gut; and promote a healthy microbiome. These modes-of-action mean SYN-020 has the potential to address multiple metabolic and inflammatory disorders and diseases associated with aging. SYN-020 was well tolerated in Phase 1 clinical studies and is now poised to enter Phase 2 clinical testing with Rasayana.
“We are extremely pleased to complete the license of SYN-020 to Rasayana, which will enable the advancement of this important GI asset from our portfolio while we focus on our lead pancreatic cancer program, VCN-01,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We believe SYN-020 is a highly versatile asset with therapeutic opportunities in multiple high-value indications arising from GI dysfunction. The Rasayana team and advisors are world leaders in IAP and its clinical applications, and they are well positioned to advance SYN-020 development, ideally delivering benefits for patients and value for Theriva shareholders.”
“We are thrilled to partner with Theriva Biologics on the development of SYN-020,” said Vidisha Mohad, Founder and CEO of Rasayana Therapeutics. “SYN-020 offers a fundamentally innovative approach to addressing gastrointestinal dysfunction and its systemic health implications. Having worked on SYN-020 research during my postdoctoral training at Harvard, I have deep conviction in its underlying biology, scientific rigor, and therapeutic potential. Importantly, its cost-effective profile reflects our shared commitment to making transformative treatments accessible to patients who need them most. At Rasayana, we are focused on advancing therapies that target the Gut-Organ Axis to extend healthspan. SYN-020’s novel biology, strong safety profile, and compelling clinical data make it an ideal fit for our pipeline. We look forward to building on Theriva’s foundational work and accelerating this program to deliver meaningful outcomes for patients worldwide”.
Under the terms of the agreement, Rasayana is granted an exclusive, worldwide license, with the right to sublicense, to develop and commercialize SYN-020 for therapeutic and diagnostic use. Theriva received a $300,000 up-front payment at signing and is eligible for up to $16M in development and regulatory milestones, tiered single digit royalties on net product sales, and up to $22M in milestones payable upon achievement of certain annual aggregate net sales. Rasayana will assume all responsibility and costs for SYN-020 development and commercialization.
About Theriva™ Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; and (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. For more information, please visit Theriva Biologics’ website at www.therivabio.com.
About Rasayana Therapeutics, Inc.
Rasayana Therapeutics, Inc. is a biotechnology company targeting the Gut-Organ axis biology to address chronic inflammatory diseases. The company is pioneering a new class of gut-inflammation targeting therapies for gastrointestinal, cardiometabolic, and neurodegenerative diseases. Rasayana’s mission is to develop novel, cost-effective medicines that extend healthspan and improve quality of life for patients globally.
Source: Theriva Biologics, Inc.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The script at the end of 2018: The Federal Reserve continued to raise interest rates, US stocks plunged 20% from the September highs, forcing the Federal Reserve to "pivot" in January.
Goldman Sachs' head of trading believes the current US stock market is repeating the scenario of late 2018, with monetary tightening and equity market pressure. The Goldman Sachs Financial Conditions Index has tightened by about 8 points in two weeks, reaching the highest level in a year. The selloff has broadened from tech stocks to defensive sectors. Gold and equities are declining simultaneously, possibly indicating investors are selling assets to raise cash, making gold a key indicator for observing liquidity stress.

Goldman Sachs Trader “Revisits the 2018 Playbook”: Still Clearly Remembers “On December 24th, Clients Asked Why the Market Dropped So Much—And I Had No Idea”
Brian Garrett pointed out that the current adjustment in the US stock market is similar to the sharp decline in Q4 2018: the S&P 500 has already experienced 42% of the corresponding drop, and the VIX is approaching its peak just before Christmas. If history repeats itself, the bottom of this cycle may appear in January next year. However, the credit market and Federal Reserve policy have yet to provide clear signals of a bottom.
Anthropic (ANT.US) nearly “broke issue price,” but Claude knocks on the doors of “the highest peak in mathematics”! 17 million lines of Lean code used to write a candidate proof for the Riemann Hypothesis
On November 20th, Eastern Time, on its second day of trading, Anthropic's intraday price dropped to a low of $83.05, just 5 cents above the offering price of $83, and finally closed at $88.91, a decline of 8.50%. On the same day, the company's mathematician Levant Alperg announced on his personal website that he and Claude had found a candidate proof for the Riemann hypothesis, which has puzzled the mathematics community for 167 years, and released about 17 million lines of Lean formalized code.

As US stocks plummet, the parent company of GTA 6 rises against the market! First-day sales hit a record $3.79 billion; Wall Street shifts focus to next-generation GTA Online.
According to Rentrak data, the global box office of "Grand Theft Auto VI" has also surpassed that of "Avengers: Endgame," the highest-grossing film of all time, which has a global box office of approximately $2.94 billion.

